Sort by
Refine Your Search
-
Listed
-
Category
-
Program
-
Employer
-
Field
-
Therapy Accelerator The Medical Research Council (MRC), as part of UK Research and Innovation (UKRI), have invested a total of £30m over 4 years through the Strategic Priorities Fund to establish a nucleic
-
Therapy Accelerator The Medical Research Council (MRC), as part of UK Research and Innovation (UKRI), have invested a total of £30m over 4 years through the Strategic Priorities Fund to establish a nucleic
-
practice, policy or regulations. The NC3Rs has an annual budget of approximately £10.5M and is primarily funded by Government through the Medical Research Council (MRC) and Biotechnology and Biological
-
to prevent, diagnose and treat illnesses such as cancer, heart disease, stroke, infections, and neurodegenerative diseases. An independent organisation, its founding partners are the Medical Research Council
-
Nucleic Acid Therapy Accelerator The Medical Research Council (MRC), as part of UK Research and Innovation (UKRI), have invested a total of £30m over 4 years through the Strategic Priorities Fund
-
innovation. UK Research and Innovation is a new entity that brings together nine partners to create an independent organisation with a strong voice for research and innovation, more information can be found
-
the Medical Research Council, with support from the Biotechnology and Biological Sciences Research Council (BBSRC) and Economic and Social Research Council (ESRC). We are seeking to recruit a research associate
-
innovation. UK Research and Innovation is a new entity that brings together nine partners to create an independent organisation with a strong voice for research and innovation, more information can be found
-
established researchers. Scientists are drawn to the LMB from all over the world, thus creating a lively and international community for the exchange of ideas and technical innovation. UK Research and
-
Accelerator The Medical Research Council (MRC), as part of UK Research and Innovation (UKRI), have invested a total of £30m over 4 years through the Strategic Priorities Fund to establish a nucleic acid therapy